The hyperviscosity syndromes

被引:81
作者
Kwaan, HC [1 ]
Bongu, A [1 ]
机构
[1] Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA
关键词
hyperviscosity; hemorheology; cancer; thrombosis; hemostasis;
D O I
10.1055/s-2007-994921
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Impaired blood flow due to abnormal theologic characteristics results in a multiplicity of clinical manifestations, collectively termed the hyperviscosity syndrome. A basic knowledge of the principles of rheology is important in the understanding of its pathophysiology, especially the relationship between viscosity and flow conditions. The flow characteristics in different types of blood vessels are also determinants in the location of the clinical manifestation. The syndrome can occur in a wide variety of diseases and is best grouped according to the causative element or elements in blood. Abnormalities in the cellular components of blood can occur in the quantity and the quality of erythrocytes, leukocytes, and platelets, Abnormal plasma components can also be in both the quantity and quality of the plasma proteins. Clinical manifestations are the result of vascular occlusion, especially in the microcirculation, The altered theologic characteristics of either the cellular or the protein component may be temperature dependent, being abnormal only at temperatures below 37 degrees C, so that only the cooler parts of the body are affected. The management of these conditions should be primarily directed at the removal of the abnormal component. At the same time, it should be accompanied by measures that can control the production of the causative element.
引用
收藏
页码:199 / 208
页数:10
相关论文
共 99 条
[1]  
ALBELDA SM, 1994, HDB IMMUNOPHARMACOLO, P71
[2]   Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia [J].
Aul, C ;
Gattermann, N ;
Germing, U ;
Sudhoff, T ;
Hollmig, KA ;
Heyll, A .
LEUKEMIA RESEARCH, 1997, 21 (03) :249-253
[3]  
BAKER RI, 1988, EUR J HAEMATOL, V40, P267
[4]   THROMBOHEMORRHAGIC COMPLICATIONS IN 101 CASES OF MYELOPROLIFERATIVE DISORDERS - RELATIONSHIP TO PLATELET NUMBER AND FUNCTION [J].
BARBUI, T ;
CORTELAZZO, S ;
VIERO, P ;
BASSAN, R ;
DINI, E ;
SEMERARO, N .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (11) :1593-1599
[5]  
BELL WR, 1973, THROMB DIATH HAEMOST, P371
[6]   EXTREME LEUKOCYTOSIS AND PROGNOSIS OF NEWLY DIAGNOSED PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA [J].
BERG, J ;
VINCENT, PC ;
GUNZ, FW .
MEDICAL JOURNAL OF AUSTRALIA, 1979, 1 (11) :480-482
[7]  
Berlin NI, 1997, SEMIN HEMATOL, V34, P1
[8]  
BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003
[9]   IDENTIFICATION OF AN INDUCIBLE ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE [J].
BEVILACQUA, MP ;
POBER, JS ;
MENDRICK, DL ;
COTRAN, RS ;
GIMBRONE, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (24) :9238-9242
[10]  
BLOCH KJ, 1973, SEMIN HEMATOL, V10, P113